Aarti Drugs Ltd (AARTIDRUGS) — shareholding pattern, promoter holding, financials and share price
About Aarti Drugs Ltd (AARTIDRUGS)
Aarti Drugs Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as AARTIDRUGS and on the BSE under scrip code 524348. Its ISIN is INE767A01016.
Established in the year 1984 and a part of $1000 million Aarti Group of Industries, Aarti Drugs Ltd. (ADL) is engaged into manufacturing and selling Active Pharmaceutical Ingredients (API's), Pharma Intermediates, Specialty Chemicals as well as Formulations. [1] It is exporting its API's and Speciality chemicals to over 100 countries across the globe. [2]
Aarti Drugs Limited is an integrated Indian manufacturer of APIs, pharmaceutical intermediates, specialty chemicals and formulations, operating GMP-certified plants with an in-house formulations arm (Pinnacle Life Science) focused on regulated market dossiers and contract manufacturing.
Operationally the company reported consolidated Q3 FY26 revenue of INR602.9 crores (+8% YoY) with EBITDA of INR56.3 crores and a 9.3% EBITDA margin; PAT rose sharply to INR40.5 crores (+58% YoY) driven by improved volumes and mix despite short-term utilization and pricing headwinds.
Listed peers in Pharmaceuticals: Gujarat Themis Biosyn Ltd, Gufic BioSciences Ltd, SMS Pharmaceuticals Ltd, Novartis India Ltd, Morepen Laboratories Ltd, Panacea Biotec Ltd.
Valuation & Returns
10 Jul 2026At ₹397.7 a share on 10 Jul 2026, Aarti Drugs Ltd (AARTIDRUGS) was valued at a price-to-earnings ratio of 18.62x against an industry P/E of 36.41x and a price-to-book of 2.65x on a book value of ₹149.99 per share as of Mar 2025. Solomo computes return on equity of 14.24% and return on capital employed of 12.33% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 18.62x
- Industry P/E
- 36.41x
- P/B
- 2.65x
- EPS (TTM)
- ₹21.36
- Book value / share
- ₹149.99
- ROE
- 14.24%
- ROCE
- 12.33%
- ROA
- 7.57%
- Debt / equity
- 0.45x
- Dividend yield
- 0.5%
- EBITDA margin
- 12.15%
- 52-week range
- ₹318.6 – ₹574.95
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Aarti Drugs Ltd (AARTIDRUGS) reported revenue of ₹2,565 crore, net profit of ₹195 crore and earnings per share of ₹21.36. That compares with revenue of ₹2,387 crore and net profit of ₹168 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹720 crore and net profit ₹55 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 2,489 | 2,716 | 2,529 | 2,387 | 2,565 |
| Net profit (₹ cr) | 205 | 166 | 172 | 168 | 195 |
| EPS (₹) | 22.14 | 17.96 | 18.65 | 18.42 | 21.36 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 7.12% | 5.86% | -1.16% | -5.60% |
| Profit growth | 10.08% | 3.00% | -6.91% | -2.03% |
| Stock price CAGR | 13% | -10% | -6% | -19% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 54.43% of Aarti Drugs Ltd (AARTIDRUGS) (down 0.6 pp QoQ), foreign institutional investors (FII) hold 1.52% and domestic institutional investors (DII) hold 10.29%. Promoters have pledged 2.5% of their holding. Market capitalisation was ₹3,630 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: DSP Small Cap Fund 7.93%, Harit Pragji Shah 2.67%, ICICI Prudential Pharma Healthcare And Diaganostics (P.H.D) Fund 2.04%, Jayshree Harit Shah 1.78%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 54.43% | 2.5% | 1.52% | 10.29% | 45.57% |
| Mar 2026 | 55.03% | 2.5% | 1.58% | 10.22% | 44.97% |
| Dec 2025 | 55.03% | - | 2.15% | 10.12% | 44.97% |
| Sep 2025 | 54.72% | - | 2.69% | 9.9% | 45.28% |
| Jun 2025 | 55.22% | - | 2.26% | 9.94% | 44.78% |
| Mar 2025 | 55.48% | - | 2.25% | 9.7% | 44.52% |
| Dec 2024 | 55.38% | - | 2.28% | 8.77% | 44.62% |
| Sep 2024 | 55.64% | - | 2.5% | 7.84% | 44.36% |